Maricar Malinis

Maricar Malinis

Auto-generated profile, based on publicly available information

Maricar Malinis

Division of Infectious Diseases Department of Medicine Vanderbilt University Medical Center Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2019 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
MMMaricar Malinis
Maricar Malinis
HBHelen W. Boucher
Helen W. Boucher
OPon behalf of the AST Infectious Diseases Community of Practice
on behalf of the AST Infectious Diseases Community of Practice

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
CRChristopher Radcliffe
Christopher Radcliffe
CPCarlo Foppiano Palacios
Carlo Foppiano Palacios
Marwan M. AzarMarwan M. Azar
Marwan M. Azar
ECElizabeth Cohen
Elizabeth Cohen
MMMaricar Malinis
Maricar Malinis
The SARS-CoV-2 pandemic continues to place a substantial burden on healthcare systems. Outpatient therapies for mild-to-moderate disease have reduced hospitalizations and deaths in clinical trials, but the real-world effectiveness of monoclonal antibodies and oral antiviral agents in solid organ transplant recipients (SOTR) with coronavirus disease-2019 (COVID-19) is largely uncharacterized. We conducted a single-center, retrospective review of 122 SOTR diagnosed with COVID-19 in the outpatient setting during the Omicron surge to address this knowledge gap. The mean age was 54 years, 57% were males, and 67% were kidney transplant recipients. The mean time from transplant to COVID-19 diagnosis was 75 months. Forty-nine (40%) received molnupiravir, 24 (20%) received sotrovimab, and 1 (0.8%) received nirmatrelvir/ritonavir. No outpatient therapy was administered in 48 (39%). All 122 SOTR had >30 days follow-up. Rates of hospitalization within 30 days of initiating therapy for molnupiravir, nirmatrelvir/ritonavir, and sotrovimab were 16% (8/49), 0% (0/1), and 8% (2/24), respectively, compared to 27% (13/48) in patients without outpatient therapy. There were no deaths in those who received any therapy versus 3 (6%) deaths in patients without outpatient therapy (p = .002). Overall, our experience suggests a role for monoclonal antibodies and oral antiviral agents in reducing COVID-19-related morbidity and mortality in SOTR.

30 December 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
MHMadeleine R. Heldman
Madeleine R. Heldman
OKOlivia S. Kates
Olivia S. Kates
KSKassem Safa
Kassem Safa
CKCamille N. Kotton
Camille N. Kotton
SGSarah J. Georgia
Sarah J. Georgia
ALAjit P. Limaye
Ajit P. Limaye
Mortality among patients hospitalized for COVID-19 has declined over the course of the pandemic. Mortality trends specifically in solid organ transplant recipients (SOTR) are unknown. Using data from a multicenter registry of SOTR hospitalized for COVID-19, we compared 28-day mortality between early 2020 (March 1, 2020–June 19, 2020) and late 2020 (June 20, 2020–December 31, 2020). Multivariable logistic regression was used to assess comorbidity-adjusted mortality. Time period of diagnosis was available for 1435/1616 (88.8%) SOTR and 971/1435 (67.7%) were hospitalized: 571/753 (75.8%) in early 2020 and 402/682 (58.9%) in late 2020 (p < .001). Crude 28-day mortality decreased between the early and late periods (112/571 [19.6%] vs. 55/402 [13.7%]) and remained lower in the late period even after adjusting for baseline comorbidities (aOR 0.67, 95% CI 0.46–0.98, p = .016). Between the early and late periods, the use of corticosteroids (≥6 mg dexamethasone/day) and remdesivir increased (62/571 [10.9%] vs. 243/402 [61.5%], p < .001 and 50/571 [8.8%] vs. 213/402 [52.2%], p < .001, respectively), and the use of hydroxychloroquine and IL-6/IL-6 receptor inhibitor decreased (329/571 [60.0%] vs. 4/492 [1.0%], p < .001 and 73/571 [12.8%] vs. 5/402 [1.2%], p < .001, respectively). Mortality among SOTR hospitalized for COVID-19 declined between early and late 2020, consistent with trends reported in the general population. The mechanism(s) underlying improved survival require further study.

8 June 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
MMMaricar Malinis
Maricar Malinis
ECElizabeth Cohen
Elizabeth Cohen
Marwan M. AzarMarwan M. Azar
Marwan M. Azar
The COVID-19 pandemic has disproportionately impacted immunosuppressed patients, including solid organ transplant recipients (SOTR). COVID-19-associated mortality among SOTR was estimated at 20.5% in the early phase of the pandemic(1). SARS-CoV-2 vaccination may help reduce the morbidity and mortality of COVID-19 among SOTR. Under emergency use authorization, the US Food Drug Administration approved two SARS-CoV-2 messenger RNA vaccines [BNT162b2 (Pfizer), mRNA-1273 (Moderna)] and an adenovirus vector-based vaccine [Ad26.COV2.S (Johnson and Johnson)].

12 July 2021 in Transplant Infectious Disease
Verified
Journal Article
Closed access
PDF file
KLKathleen A. Linder
Kathleen A. Linder
CKChristopher Kovacs
Christopher Kovacs
KMKate M. Mullane
Kate M. Mullane
CWCameron Wolfe
Cameron Wolfe
NCNina M Clark
Nina M Clark
DKDaniel R. Kaul
Daniel R. Kaul

17 October 2024 in New England Journal of Medicine
Verified
Journal Article
Open access
CDChristine M. Durand
Christine M. Durand
AMAllan Massie
Allan Massie
SFSander Florman
Sander Florman
TLTao Liang
Tao Liang
MRMeenakshi M. Rana
Meenakshi M. Rana
DSDorry L. Segev
Dorry L. Segev
Kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ Policy Equity Act and is currently approved for research only. The Department of Health and Human Services is considering expanding the procedure to clinical practice, but data are limited to small case series that did not include donors without HIV as controls. In an observational study conducted at 26 U.S. centers, we compared transplantation of kidneys from deceased donors with HIV and donors without HIV to recipients with HIV. The primary outcome was a safety event (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic infection), assessed for noninferiority (margin for the upper bound of the 95% confidence interval, 3.00). Secondary outcomes included overall survival, survival without graft loss, rejection, infection, cancer, and HIV superinfection. We enrolled 408 transplantation candidates, of whom 198 received a kidney from a deceased donor; 99 received a kidney from a donor with HIV and 99 from a donor without HIV. The adjusted hazard ratio for the composite primary outcome was 1.00 (95% confidence interval [CI], 0.73 to 1.38), which showed noninferiority. The following secondary outcomes were similar whether the donor had HIV or not: overall survival at 1 year (94% vs. 95%) and 3 years (85% vs. 87%), survival without graft loss at 1 year (93% vs. 90%) and 3 years (84% vs. 81%), and rejection at 1 year (13% vs. 21%) and 3 years (21% vs. 24%). The incidence of serious adverse events, infections, surgical or vascular complications, and cancer was similar in the groups. The incidence of HIV breakthrough infection was higher among recipients of kidneys from donors with HIV (incidence rate ratio, 3.14; 95%, CI, 1.02 to 9.63), with one potential HIV superinfection among the 58 recipients in this group with sequence data and no persistent failures of HIV treatment. In this observational study of kidney transplantation in persons with HIV, transplantation from donors with HIV appeared to be noninferior to that from donors without HIV. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT03500315.).